Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab OncologyALMOF 12 Debt-to-Equity is 0.07 as of Dec. 2025, which is 30% below its 10-year median of 0.10. GuruFocus rates ALMOF with a GF Score™ of 12/100 and a GF Value™ of $0.87 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 956 Biotechnology companies, Alphamab Oncology ranks better than 65.06% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Alphamab Oncology's Debt-to-Equity or its related term are showing as below:
ALMOF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.42 Med: 0.1 Max: 0.34
Current: 0.07
During the past 9 years, the highest Debt-to-Equity Ratio of Alphamab Oncology was 0.34. The lowest was -0.42. And the median was 0.10.
ALMOF's Debt-to-Equity is ranked better than 65.06% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs ALMOF: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Alphamab Oncology Debt-to-Equity Related Terms
Alphamab Oncology Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALMOF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Alphamab Oncology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (ALMOF) has a Debt-to-Equity of 0.07 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alphamab Oncology and its competitors. This is 30% below median its historical median of 0.10. According to the industry distribution chart, Alphamab Oncology ranks #334 out of 956 companies in the Biotechnology industry, placing it in the top 34.9%.
Is Alphamab Oncology's Debt-to-Equity too high?
Alphamab Oncology's current Debt-to-Equity of 0.07 is 30% below median its 10-year median of 0.10. The Biotechnology industry median Debt-to-Equity is 0.16. Alphamab Oncology's value of 0.07 is 56.3% below this industry median. Based on the distribution chart, Alphamab Oncology ranks #334 out of 956 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alphamab Oncology has a GF Score™ of 12/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #334 out of 956 companies for Debt-to-Equity. This puts Alphamab Oncology in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Alphamab Oncology's value of 0.07 is 56.3% below this benchmark. While the company's 10-year median is 0.10 vs. the industry median of 0.16, Alphamab Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alphamab Oncology's current Debt-to-Equity of 0.07 is 56.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alphamab Oncology and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphamab Oncology's current Debt-to-Equity is 0.07, which is 30% below median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (ALMOF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.02 — trading 17.4% above its estimated fair value. The current Debt-to-Equity is 0.07, which is 30% below median its 10-year median of 0.10 and 56.3% below the Biotechnology industry median of 0.16. Alphamab Oncology's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Alphamab Oncology (ALMOF), the current Debt-to-Equity is 0.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (ALMOF) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of $1.02 is trading 17.4% above its estimated GF Value™ of $0.87.
GuruFocus considers Alphamab Oncology to be Modestly Overvalued.
Key valuation signals for ALMOF:
Debt-to-Equity: 0.07 (30% below median its 10-year median of 0.10)
GF Value™: $0.87 vs. price of $1.02 (17.4% above fair value)
Industry Position: 56.3% below the Biotechnology median (#334 of 956)
No single metric tells the full story. See the ALMOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
12GF Score
Get the complete analysis for ALMOF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMOF has been successfully added to your 
